Article
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy.
ESMO open - 1 Feb 2023
Fendl B, Berghoff A S, Preusser M, Maier B
Abstract excerpt
The introduction of immune checkpoint inhibitors (ICIs) for the treatment of solid cancers dramatically turned the tables in clinical routine. However, therapy success is still limited with up to 70% of non-responders in patients with ICI treatment. Traditionally, most immunotherapy approaches aim at directly stimulating anti-tumor T cell responses. More recently, tumor-associated macrophages have come into focus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.